Update on alzheimer's disease therapeutics

Reviews on Recent Clinical Trials

Volumn 8, Issue 2, 2013, Pages 110-118

  Rafii, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Anti amyloid treatment; Mild Cognitive Impairment; Prodromal Alzheimer's disease

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AVAGACESTAT; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; BEXAROTENE; CEREBROLYSIN; DONEPEZIL; ELND 005; EVP 6124; GAMMA SECRETASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; ISPRONICLINE; MK 8931; NICOTINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SOLANEZUMAB; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG; VANUTIDE CRIDIFICAR;

ALZHEIMER DISEASE; DRUG SAFETY; DRUG TOLERABILITY; GENE THERAPY; HUMAN; IMMUNOTHERAPY; MISSENSE MUTATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TREATMENT OUTCOME; VACCINATION;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY;

EID: 84884393956     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/15748871113089990045     Document Type: Review

References (61)

1. Bartus RT, Dean RL, Beer B 3rd, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217(4558): 408-17.
2. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215(4537): 1237-9.
3. Selkoe DJ. Alzheimer's disease. Cold Spring Harb Perspect Biol 2011; 3(7).
4. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192(1): 106-13.
5. Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol 2011; 70(6): 871-80.
6. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8(9): 663-72.
7. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8(2): 101-12.
8. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005; 120(4): 545-55.
9. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012; 488(7409): 96-9.
10. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008; 7(6): 483-93. Epub 2008. Erratum in: Lancet Neurol 2008; 7(7): 575. Lancet Neurol 2011; 10(4): 297.
11. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398(6727): 518-22.
12. Dasilva KA, Shaw JE, McLaurin J. Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention. Exp Neurol 2010; 223(2): 311-21.
13. Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, et al. A phase 2 randomized trial of ELND005, scylloinositol, in mild to moderate Alzheimer disease. Neurology 2011; 77(13): 1253-62.
14. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012; 11(7): 597-604.
15. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61(1): 46-54.
16. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64(9): 1553-62.
17. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, et al, Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009; 6(2): 144-51.
18. Pihlgren M, Madani R, Hickman D, Giriens V, Chuard N, ven der Auwera I, et al. The safety profile of ACI-24, an oligo-specific amyloid beta vaccine, demonstrated decrease of large microbleedings in brain of aged Alzheimer's disease mouse model. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2012; 5(4): Supplement, p425-426.
19. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010; 6(2): 108-19. Review. Erratum in: Nat Rev Neurol 2010; 6(4): 183. Nat Rev Neurol 2010; 6(6): 296.
20. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012; 8(4): 261-71.
21. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73(24): 2061-70.
22. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cellmediated removal of human amyloid-β. J Alzheimers Dis 2012; 28(1): 49-69.
23. Schwartz SA. Intravenous immunoglobulin treatment of immunodeficiency disorders. Pediatr Clin North Am 2000; 47(6): 1355-69.
24. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al, ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science. 2012; 335(6075): 1503-6.
25. Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease. J Neurosci 2012; 32(30): 10117-28.
26. Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. " Science 2013; 340(6135).
27. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, Felsenstein KM. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. " Science 2013; 340(6135).
28. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D'Hooge R, De Strooper B. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. " Science 2013; 340(6135).
29. Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. " Science 2013; 340(6135).
30. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008; 118(2): 671-82.
31. Koldamova R, Lefterov I. Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease-implications for a new therapeutic approach. Curr Alzheimer Res 2007; 4(2): 171-8.
32. Goedert M. Tau protein and neurodegeneration. Semin Cell Dev Biol 2004; 15(1): 45-9.
33. Iqbal K, Alonso AC, Gong CX, Khatoon S, Pei JJ, Wang JZ, Grundke-Iqbal I. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. J Neural Transm Suppl 1998; 53: 169-80.
34. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 2002; 99(9): 6364-9.
35. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 2012; 32(11): 3601-11.
36. Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000; 56(3): 247-250.
37. Medina DX, Caccamo A, Oddo S. Methylene blue reduces aBeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 2011; 21(2): 140-149.
38. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011; 118(4): 658-67.
39. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010; 224(2): 472-85.
40. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R. Preparation and characterization of neurotoxic tau oligomers. Biochemistry 2010; 49(47): 10039-41.
41. Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, et al. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology 2012; 62(2): 1099-110.
42. Wang HY, Bakshi K, Shen C, Frankfurt M, Trocmé-Thibierge C, Morain P. S 24795 limits beta-amyloid-alpha7 nicotinic receptor interaction and reduces Alzheimer's disease-like pathologies. Biol Psychiatry 2010; 67(6): 522-30.
43. Mousavi M, Hellström-Lindahl E. Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem Int 2009; 54(3-4): 237-44.
44. King MV, Marsden CA, Fone KC. A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends in Pharmacological Sciences 2008; 29(9): 482-92.
45. Maher-Edwards G, Zvartau-Hind M, Hunter AJ, Gold M, Hopton G, Jacobs G, Davy M, Williams P. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr Alzheimer Res 2010; 7(5): 374-85.
46. Hefti, F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 1986; 6(8): 2155-62.
47. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187-1192.
48. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. Insulindegrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci 2003; 100: 4162-4167.
49. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2012; 9(1): 35-66.
50. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69(1): 29-38
51. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci USA 2000; 97(10): 5440-4.
52. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006; 13(1): 43-54.
53. Stewart WF, Kawas C, Corrada M, Metter EJ Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48(3): 626-32.
54. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008; 70(19): 1672-7.
55. Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, Zandi PP. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008; 70(1): 17-24.
56. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289(21): 2819-26.
57. Reines S. A., Block G. A., Morris J. C., Liu G., Nessly M. L., Lines C. R., Norman B. A., Baranak C. C. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 66-71.
58. ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. Cognitive function over time in the Alzheimer's Disease Antiinflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008; 65(7): 896-905.
59. Breitner J. C. (2009). "A bi-directional effect of naproxen on the pathogenesis of AD: clinical and biological evidence from a randomized primary prevention trial, " in Clinical Trials on Alzheimer's Disease, Las Vegas: Abstract O11.
60. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 77(6): 556-63.
61. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gómez CM, Jaramillo-Elorza MC, Moreno S, Aguirre-Acevedo DC, Saldarriaga A, Lopera F. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol 2011; 10(3): 213-20.